InsiderTrades.com logo
Mark Hopman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Mark Hopman Biography and Net Worth

Insider of Beta Bionics

Mark brings over 22 years of healthcare experience to Beta Bionics where he leads commercialization efforts. A seven year veteran of Dexcom, Mark was instrumental in conceiving and building Dexcom’s pharmacy efforts from 2014-2021. Mark is a registered pharmacist in Ohio where he first practiced after graduating pharmacy school from The Ohio State University. He also has his MBA from Xavier University in Cincinnati Ohio.

What is Mark Hopman's net worth?

The estimated net worth of Mark Hopman is at least $967.04 thousand as of September 5th, 2025. Hopman owns 31,215 shares of Beta Bionics stock worth more than $967,041 as of December 4th. This net worth estimate does not reflect any other investments that Hopman may own. Learn More about Mark Hopman's net worth.

How do I contact Mark Hopman?

The corporate mailing address for Hopman and other Beta Bionics executives is 11 HUGHES, IRVINE, CA, 92618. Beta Bionics can also be reached via phone at (949) 427-7785 and via email at [email protected]. Learn More on Mark Hopman's contact information.

Has Mark Hopman been buying or selling shares of Beta Bionics?

Mark Hopman has not been actively trading shares of Beta Bionics during the past quarter. Most recently, Mark Hopman sold 11,411 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $20.56, for a transaction totalling $234,610.16. Following the completion of the sale, the insider now directly owns 31,215 shares of the company's stock, valued at $641,780.40. Learn More on Mark Hopman's trading history.

Who are Beta Bionics' active insiders?

Beta Bionics' insider roster includes Stephen Feider (CFO), Mark Hopman (Insider), Mike Mensinger (Insider), and Steven Russell (Insider). Learn More on Beta Bionics' active insiders.

Are insiders buying or selling shares of Beta Bionics?

In the last twelve months, Beta Bionics insiders bought shares 2 times. They purchased a total of 1,033,350 shares worth more than $17,566,950.00. In the last twelve months, insiders at the sold shares 18 times. They sold a total of 76,232 shares worth more than $1,471,002.63. The most recent insider tranaction occured on October, 31st when Director Adam Lezack sold 1,406 shares worth more than $37,779.22. Learn More about insider trades at Beta Bionics.

Information on this page was last updated on 10/31/2025.

Mark Hopman Insider Trading History at Beta Bionics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/5/2025Sell11,411$20.56$234,610.1631,215View SEC Filing Icon  
9/4/2025Sell6,818$19.97$136,155.4631,215View SEC Filing Icon  
9/2/2025Sell848$18.86$15,993.2833,284View SEC Filing Icon  
8/19/2025Sell16,158$16.61$268,384.3834,132View SEC Filing Icon  
6/2/2025Sell868$17.89$15,528.5234,132View SEC Filing Icon  
See Full Table

Mark Hopman Buying and Selling Activity at Beta Bionics

This chart shows Mark Hopman's buying and selling at Beta Bionics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beta Bionics Company Overview

Beta Bionics logo
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Read More

Today's Range

Now: $30.00
Low: $29.56
High: $31.51

50 Day Range

MA: $25.15
Low: $19.53
High: $31.51

2 Week Range

Now: $30.00
Low: $8.89
High: $32.71

Volume

2,652,084 shs

Average Volume

474,329 shs

Market Capitalization

$1.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A